eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
3/2023
vol. 25
 
Share:
Send email
Share:
Review paper

Herbal medicinal products in RESPIRATORY diseases – STANce of the Polish PHYTOtherapy Association – STANPHYTO RESPIRATORY II

Zbigniew Doniec
1, 2
,
Mirosława Krauze-Baranowska
3
,
Mieczysława Czerwionka-Szaflarska
4
,
Ernest Kuchar
5
,
Izabela Fecka
6
,
Adam Sybilski
7, 8
,
Jarosław Woroń
9
,
Agnieszka Mastalerz-Migas
10

  1. Pneumology Department, Institute of Tuberculosis and Lung Diseases, Field Branch, Rabka-Zdroj, Poland
  2. Medical Institute, Podhale State College of Applied Science, Nowy Targ, Poland
  3. Department of Pharmacognosy, Medical University of Gdansk, Poland
  4. A. Jurasz University Hospital, Department of Paediatrics, Allergology and Gastroenterology Clinic, Bydgoszcz, Poland
  5. Department of Paediatrics and Observation Unit, Medical University of Warsaw, Poland
  6. Department of Pharmacognosy and Herbal Medicines, Medical University of Wroclaw, Poland
  7. Department of Paediatric and Neonatal Diseases, National Medical Institute of the Ministry of Internal Affairs and Administration in Warsaw, Poland
  8. Department of Paediatrics II, Postgraduate Medical Education Center, Warsaw, Poland
  9. Department of Clinical Pharmacology, Jagiellonian University, Collegium Medicum of Cracow, Poland
  10. Chair and Department of Family Practice, Medical University of Wroclaw, Poland
Family Medicine & Primary Care Review 2023; 25(3): 331–338
DOI: https://doi.org/10.5114/fmpcr.2023.131271
Online publish date: 2023/09/30
Article file
- 16 FM&PCR 3 23 - R - Doniec - Herbal medicinal products II.pdf  [0.56 MB]
Get citation
 
PlumX metrics:
 
1. Assessment report on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix. 29 September 2015, EMA/HMPC/444251/ 2015, Committee on Herbal Medicinal Products (HMPC). Available from URL: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-pelargonium-sidoides-dc/pelargonium-reniforme-curt-radix-revision-1_en.pdf.
2. Kayser O,  Kolodziej H. Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme. Planta Med 1997; 63(6): 508–510, doi: 10.1055/s-2006-957752.
3. Michaelis M,  Doerr HW, Cinatl J Jr. Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine 2011; 18(5): 384–386, doi: 10.1016/j.phymed.2010.09.008.
4. Luna LA Jr,  Bachi ALL, Novaes e Brito AE, et al. Immune responses induced by Pelargonium sidoides extract in serum and nasal mucosa of athletes after exhaustive exercise: modulation of secretory IgA, IL-6 and IL-15. Phytomedicine 2011; 18(4): 303–308, doi: 10.1016/j.phymed.2010.08.003. 
5. Schapowal A, Dobos G, Cramer H, et al. Treatment of signs and symptoms of the common cold using EPs 7630 – results of a meta-analysis. Heliyon 2019; 5(11): e02904, doi: 10.1016/j.heliyon.2019.e02904. 
6. Agbabiaka TB,  Guo R, Ernst E. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. Phytomedicine 2008; 15(5): 378–385, doi: 10.1016/j.phymed.2007.11.023.
7. Timmer A, GüntherJ, Motschall E, et al. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev 2013; 10: CD006323, doi: 10.1002/14651858.CD006323.pub3.
8. Careddu D, Pettenazzo A. Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children. Int J Gen Med 2018; 11: 91–98, doi: 10.2147/IJGM.S154198. 
9. Tahan F, Yaman M. Can the Pelargonium sidoides root extract EPs® 7630 prevent asthma attacks during viral infections of the upper respiratory tract in children? Phytomedicine 2013; 20(2): 148–150, doi: 10.1016/j.phymed.2012.09.022.
10. Balicka O. Znaczenie pelargonii afrykańskiej w terapii infekcji górnych dróg oddechowych na podstawie przeglądu badań klinicznych [Praca magisterska]. Gdańsk: Gdański Uniwersytet Medyczny; 2021 (in Polish).
11. Assessment report on Allium cepa L., bulbus. 27 March 2012 EMA/HMPC/347195/2011 Committee on Herbal Medicinal Products (HMPC). Available from URL: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-allium-cepa-l-bulbus_en.pdf.
12. Kim JH. Anti-bacterial action of onion (Allium cepa L.) extracts against oral pathogenic bacteria. J Nihon Univ Sch Dent 1997; 39(3): 136–141.
13. Benkeblia N. Antimicrobial activity of essential oil extracts of various onions (Allium cepa) and garlic (Allium sativum). LWT – Food Science and Technology 2004; 37(2): 263–268,
14. Rose P, Whiteman M, Moore PK, et al. Bioactive S-alk(en)yl cysteine sulfoxide metabolites in the genus Allium: the chemistry of potential therapeutic agents. Nat Prod Rep 2005; 22(3): 351–368.
15. Liguori L, Califano R, Albanese D. Chemical composition and antioxidant properties of five white onion (Allium cepa L.) landraces. J Food Qual 2017, doi: 10.1155/2017/6873651.
16. Assessement Report on Urtica Dioica L., Urtica Urens L., herba. EMA. Available from URL: https://www.ema.europa.eu/en/documents/herbal-report/assessment-report-urtica-dioica-l-urtica-urens-l-herba_en.pdf
17. Assessment report on Matricaria recutita L., flos and Matricaria recutita L., aetheroleum. 7 July 2015 EMA/HMPC/55837/2011 Committee on Herbal Medicinal Products (HMPC). Available from URL: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-matricaria-recutita-l-flos-matricaria-recutita-l-aetheroleum-first-version_en-0.pdf.
18. Szopa A, Kubica P, Ekiert H. Ekologia, skład chemiczny, działanie prozdrowotne oraz badania biotechnologiczne aronii czarnoowocowej (Aronia melanocarpa (Michx.) Elliott), aronii czerwonej, (Aronia arbutifolia (L.) Pers.) i aronii śliwolistnej, (Aronia × prunifolia (Marsh.) Rehd.) Fitoter 2017; 18(2): 145–157, doi: 10.25121/PF.2017.16.2.145 (in Polish).
19. Wosikowski K, Seifert SS, Melnykov O, et al. Imupret (R) inhibits respiratory syncytial virus replication and displays in vitro and in vivo immunomodulatory properties. Planta Medica 2013; 79(13): 1152–1152.
20. Tran HTT, Peterburs P, Seibel J, et al. In vitro Screening of Herbal Medicinal Products for Their Supportive Curing Potential in the Context of SARS-CoV-2. Evid Based Complement Alternat Med 2022; 2022: 8038195, doi: 10.1155/2022/8038195.
21. Hostanska K, Melzer J, Saller R. Anti-inflammatory abilities of Imupret®: Inhibition of IL8 and human β-defensin 2 induced by LPS and IL1 β in lung epithelial A549 cells. Eur J Integr Med 2008; 1: 12–12, doi: 10.1016/j.eujim.2008.08.105.
22. Pahl A. Imupret® modulates the innate and adaptive immune system parameters in vitro. Planta Medica 2009; 75(9), doi: 10.1055/s-0029-1235005.
23. Vavilova VP, Abramov-Sommariva D, Steindl H, et al. Effectiveness and tolerability of Tonsilgon® N in the treatment of recurrent upper respiratory tract infections in children: a non-interventional study in Russia. Clinical Phytoscience 2016; 2(6), doi: 10.1186/s40816-016-0020-9.
24. Berger T. Tolerability and efficacy of a herbal combination preparation in children and adolescents with recurrent infections of the upper respiratory tract. MMW Fortschr Med 2008; 150(Suppl. 2): 85–90.
25. Popovych V, Koshel I, Malofichuk A, et al. A randomized, open-label, multicenter, comparative study of therapeutic efficacy, safety and tolerability of BNO 1030 extract, containing marshmallow root, chamomile flowers, horsetail herb, walnut leaves, yarrow herb, oak bark, dandelion herb in the treatment of acutenonbacterial tonsillitis in children aged 6 to 18 years. Am J Otolaryngol 2019; 40(2): 265–273, doi: 10.1016/j.amjoto.2018.10.012.
26. Begrow F, Böckenholt C, Ehmen M, et al. Effect of myrtol standardized and other substances on the respiratory tract: Ciliary beat frequency and mucociliary clearance as parameters. Adv Ther 2012; 29: 350–358.
27. Grassmann J, Hippeli S, Dornisch K, et al. Antioxidant properties of essential oils. Possible explanations for their anti-inflammatory effects. Arzneimittelforschung 2000; 50: 135–139. 
28. Duijn HJ, van, Kuyvenhoven MM, Schellevis FG, et al. Illness behaviour and antibiotic prescription in patients with respiratory tract symptoms. Br J Gen Pract 2007; 57: 561–568.
29. Charakterystyka Produktu Leczniczego Respero Myrtol, 300 mg, kapsułki dojelitowe, miękkie (in Polish).
30. Behrbohm H, Kaschke O, Sydow K. Effect of the phytogenic secretolytic drug Gelomyrtol forte on mucociliary clearance of the maxillary sinus. Laryngorhinootologie 1995; 74: 733–737.
31. Matthys H, Mey C de, Carls C, et al. Efficacy and tolerability of myrtol standardized in acute bronchitis A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs cefuroxime and ambroxol. Arzneimittelforschung 2000; 50: 700–711. 
32. Fokkens WJ, Lund VJ,  Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020; 58(Suppl. S29): 1–464, doi: 10.4193/Rhin20.600.
33. Naser B, Lund B, Henneicke-von Zepelin HH, et al. A randomized, double-blind, placebo-controlled, clinical dose–response trial of an extract of Baptisia, Echinacea and Thuja for the treatment of patients with common cold. Phytomedicine 2005; 12: 715–722.
34. Edwards SE, Costa Rocha I, de, Williamson EM, i wsp. Fitofarmaceutyki – oparte na dowodach naukowych kompendium leczniczych produktów ziołowych. Warszawa: Wydawnictwo Lekarskie PZWL; 2022 (in Polish).
35. Assessment report on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos, 22 May 2012 EMA/HMPC/337067/2011 Committee on Herbal Medicinal Products (HMPC). Available from URL: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-tilia-cordata-miller-tilia-platyphyllos-scop-tilia-x-vulgaris-heyne-their_en.pdf.
36. Devi KP,  Malar DS,  Nabavi SF, et al. Kaempferol and inflammation: from chemistry to medicine. Pharmacol Res 2015; 99: 1–10, doi: 10.1016/j.phrs.2015.05.002. 
37. Adamczak A, Opala B, Gryszczyńska A, et al. Content of pyrrolizidine alkaloids in the leaves of coltsfoot (Tussilago farfara L.) in Poland. Acta Soc Bot Pol 2013; 82(4): 289–293, doi: 10.5586/asbp.2013.028.
38. Bota VB, Neamtu AA, Olah NK, et al. A Comparative Analysis of the Anatomy, Phenolic Profile, and Antioxidant Capacity of Tussilago farfara L. Vegetative Organs. Plants 2022; 11(13): 1663, doi: 10.3390/plants11131663.
39. Assessment report on Sambucus nigra L., flos Final, 20 March 2018 EMA/HMPC/611504/2016 Committee on Herbal Medicinal Products (HMPC). Available from URL: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-sambucus-nigra-l-flos-revision-1_en.pdf.
40. Saifulazmi NF, Rohani ER, Harun S, et al. A Review with Updated Perspectives on the Antiviral Potentials of Traditional Medicinal Plants and Their Prospects in Antiviral Therapy. Life (Basel) 2022; 12(8): 1287, doi: 10.3390/life12081287.
41. Dorsch W, Schilcher H. Ziołolecznictwo w pediatrii. Wrocław: Medpharm; 2021 (in Polish).
42. Różański M, Jankowski A. Mieszanki ziołowe o działaniu przeciwgorączkowym jako przykłady tradycyjnego leku roślinnego stosowanego w populacji pediatrycznej. Wiad Lek 2016; 69(1): 19–23 (in Polish).
43. EMA Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens. Available from URL: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-echinacea-purpurea-l-moench-herba-recens_en.pdf.
44. Gan XH, Zhang L, Heber D, et al. Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyte-target conjugates and killer cells and activation of programming for lysis. Int Immunopharmacol 2003; 3(6): 811–824.
45. Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine 2003; 10(1): 66–86.
46. Kaczor E. Znaczenie jeżówki purpurowej w profilaktyce i terapii infekcji górnych dróg oddechowych na podstawie przeglądu badań klinicznych [Praca magisterska]. Gdańsk: Gdański Uniwersytet Medyczny; 2021 (in Polish).
47. Barrett B. Efficacy and safety of Echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. J Pediatr 2004; 145(1): 135–136.
48. Huntley AL, Coon JT, Ernst E. The safety of herbal medicinal products derived from Echinacea species. A systematic review. Drug Safety 2005; 28(5): 387–400.
49. Assessment report on Aloe barbadensis Mill. and on Aloe (various species, mainly Aloe ferox Mill. and its hybrids), folii succus siccatus. 22 November 2016 EMA/HMPC/759585/2015 Committee on Herbal Medicinal Products (HMPC). Available from URL: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-aloe-barbadensis-mill-aloe-various-species-mainly-aloe-ferox-mill-its_en.pdf.
50. Cieślik E, Turcza K. Właściwości prozdrowotne aloesu zwyczajnego Aloe vera (L.) Webb. (Aloe barbadensis Mill.). Post Fitoter 2015; (16)2: 117–124 (in Polish).
51. Fal A, Conrad F, Jambor J, et al. Anti-viral activity of Biostymina® (Aloe arborescens folii recentis extractum fluidum) against viruses causing upper respiratory tract infections tested in vitro. Post Fitoter 2014; 15(3): 127–135.
52. Drozd J, Anuszewska EL. Działanie immunostymulujące wodnego wyciągu z liści aloesu drzewiastego (Aloe arborescens Mill.). Post Fitoterapii 2014; 1: 23–27 (in Polish). 
53. Anuszewska E, Drozd J, Drozd E, et al. Aktywność immunostymulująca frakcji polisacharydowych uzyskanych z produktu leczniczego Biostymina® (Aloe arborescens folii recentis extractum fluidum). Post Fitoter 2015; (16)2: 83–88 (in Polish). 
54. Prohorov EV, Ostrowskiy IM, Belskaya EA, et al. Effektivnost ispolzovaniya „Bioarona C” v lechenii ostrogo i retsidiviruyushchego bronhita u detey. Sov Pediatr 2011; 3: 81−84,
55. Schönknecht K, Kulawik AM, Krauss H, et al. Efficacy and safety of candelabra aloe extract (Aloe Arborescens Mill.) in prevention and treatment of upper respiratory tract infections of various aetiologies. Wiad Lek 2022; 75(12): 3123–3127, doi: 10.36740/WLek202212138.
56. European Union herbal monograph on Allium sativum L., bulbus, Committee on Herbal Medicinal Products (HMPC EMA/HMPC/7685/2013). Available from URL: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-allium-sativum-l-bulbus_en.pdf.
57. Assessment report on Grindelia robusta Nutt., Grindelia squarrosa (Pursh) Dunal, Grindelia humilis Hook. et Arn., Grindelia camporum Greene, herba. 20 November 2012 EMA/HMPC/748218/2011 Committee on Herbal Medicinal Products (HMPC). Available from URL: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-grindelia-robusta-nutt-grindelia-squarrosa-pursh-dunal-grindelia-humilis_en.pdf.
58. Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual epidemiological report for 2021. Available from URL: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2021.
59. Assessment report on Eucalytus globulus Labill., Eucalyptus polybractea R.T. Baker and/or Eucalyptus smithii R.T. Baker, aetheroleum. 25 March 2014 EMA/HMPC/307782/2012 Committee on Herbal Medicinal Products (HMPC). Available from URL: https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-eucalytus-globulus-labill-eucalyptus-polybractea-rt-baker/eucalyptus-smithii-rt-baker-aetheroleum_en.pdf.
60. Cermelli C, Fabio A, Fabio G, et a. Effect of Eucalyptus essential oil on respiratory bacteria and viruses. Curr Microbiol 2008; 56: 89–92. 
61. Chung KH, Yang KS, Kim J, et al. Antibacterial activity of essential oils on the growth of Staphylococcus aureus and measurement of their binding interaction using optical biosensor. J Microbiol Biotechnol 2007; 17(11): 1848–1855.
62. Kehrl W, Sonnemann U, Dethlefsen U. Therapy for acute non-purulent rhinosinusitis with cineole: results of a double-blind randomised, placebo-controlled trial. Laryngoscope 2004; 114: 738–774.
63. Tesche S, Metternich F, Sonnemann U, et al. The value of herbal medicines in the treatment of acute non-purulent rhinosinusitis. Eur Arch Otorhinolaryngol 2008; 265: 1355–1359, doi: 10.1007/s00405-008-0683-z.
64. Virgin F, Zhang S, Schuster D, et al. The bioflavonoid compound, Sinupret®, stimulates transepithelial chloride transport in vitro and in vivo. Laryngoscope 2010; 120(5): 1051–1056.
65. Azab A, Nassar A, Azab AN. Anti-Inflammatory Activity of Natural Products. Molecules 2016; 21(10): 1321, doi: 10.3390/molecules21101321.
66. Rossi A, Dehma F, Kieselbach C, et al. The novel Sinupret® dry extract exhibits anti-inflammatory effectiveness in vivo. Fitoterapia 2012; 83: 715–720, doi: 10.1016/j.fitote.2012.02.008.
67. Glatthaar-Saalmüller B, Rauchaus U, Rode S, et al. Antiviral activity in vitro of two preparations of the herbal medicinal product Sinupret against viruses causing respiratory infections. Phytomedicine 2011; 19: 1–7, doi: 10.1016/j.phymed.2011.10.010. 
68. Tcanencu I, Sandstedt K, Ismail C, et al. Anti-inflammatory effect of a herbal combination preparation in a murine model of bacterial rhinitis. Phytopharmaka und Phytotherapie 2002; October 10th–12th.
69. Biebach K, Kramer A. Effektive Behandlung der Rhinosinusitis bei Kindern. päd – Praktische Pädiatrie 2004; 10: 333–336.
70. Jund R, Mondigler M, Steindl H, et al. [Clinical efficacy of a herbal drug combination in acute viral rhinosinusitis]. MMW Fortschritte der Medizin 2015; 157(157 Suppl. 4): 6–11, doi: 10.1007/s15006-015-2934-4. 
71. Neubauer N, März RW. Placebo-controlled, randomized, double-blind clinical trial with Sinupret sugar-coated tablets on the basis of a therapy with antibiotics and decongestant nasal drops in acute sinusitis. Phytomedicine 1994; 3: 177–181, doi: 10.1016/S0944-7113(11)80061-9.
72. Seibel J, Wonnemann M, Werz O, et al. A tiered approach to investigate the mechanism of anti-inflammatory activity of an herbal medicinal product containing a fixed combination of thyme herb and primula root extracts. Clinical Phytoscience 2018; 4(1): 4, doi: 10.1186/s40816-018-0062-2.
73. Seibel J, Pergola C, Werz O, et al. Bronchipret® syrup containing thyme and ivy extracts suppresses bronchoalveolar inflammation and goblet cell hyperplasia in experimental bronchoalveolitis. Phytomedicine 2015; 22(13): 1172–1177, doi: 10.1016/j.phymed.2015.09.001.
74. Seibel JM, Pack O, Wosikowski K, et al. Bronchipret® is a potent inhibitor of citric acid-induced cough in guinea pigs and exerts beneficial effects on dysregulated goblet cell number and ciliary beat frequency. Nat Heart Lung Instit (London) 2014; 6: 26–28.
75. Seibel J, Wosikowski K, Haunschild J. A herbal medicinal product containing a fixed combination of thyme herb and ivy leaf fluid extracts (Bronchipret® Syrup) improves the pathology in LPS-induced bronchoalveolitis. Phytopharm 2013.
76. Kemmerich B, Eberhardt R, Stammer H. Efficacy and tolerability of a fluid extract combination of thyme herb and ivy leaves and matched placebo in adults suffering from acute bronchitis with productive cough. A prospective, double-blind, placebo-controlled clinical trial. Arzneimittelforschung 2006; 56: 652–660.
77. Marzian O. Treatment of acute bronchitis in children and adolescents. Noninterventional postmarketing surveillance study confirms the benefit and safety of a syrup made of extracts from thyme and ivy leaves. MMW Fortschr Med 2006; 149: 69–74.
78. Mastalerz-Migas A, Doniec Z, Płusa T. Bronchipret TE® in therapy of acute infections of the respiratory tract. Pol Merk Lek 2017; 43(258): 255–257.
Copyright: © 2023 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.